Holen Sie sich die Stockscreener-App
0.8499
0.01%
-0.000100
Handel nachbörslich:
.85
0.000100
+0.01%
Schlusskurs vom Vortag:
$0.85
Offen:
$0.83
24-Stunden-Volumen:
231.83K
Relative Volume:
0.59
Marktkapitalisierung:
$21.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.43M
KGV:
-0.2382
EPS:
-3.5677
Netto-Cashflow:
$-15.21M
1W Leistung:
+23.41%
1M Leistung:
+7.16%
6M Leistung:
+17.60%
1J Leistung:
-44.09%
1-Tages-Spanne:
$0.83
$0.89
1-Wochen-Bereich:
$0.6802
$0.9627
52-Wochen-Spanne:
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(702) 514-4174
Adresse
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.8499 | 21.20M | 0 | -20.43M | -15.21M | -3.5677 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Pasithea Therapeutics appoints chief medical officer - MSN
Pasithea Therapeutics (KTTA) CEO awarded 1.76M stock options at $0.841 - Stock Titan
Pasithea (NASDAQ: KTTA) grants director 152,783 options at $0.841 strike - Stock Titan
Pasithea Therapeutics (KTTA) director receives 152,783 stock options grant - Stock Titan
Pasithea Therapeutics (KTTA) CFO receives 1.13M-share stock option grant - Stock Titan
[Form 4] Pasithea Therapeutics Corp. Insider Trading Activity - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) grants director Emer Leahy 152,783 options - Stock Titan
Pasithea (KTTA) director receives 152,783 stock options at $0.841 - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) names Chief Medical Officer as reporting insider on Form 3 - Stock Titan
Pasithea Therapeutics Appoints Dr. Kartik Krishnan as Chief Medical Officer to Advance PAS-004 MEK Inhibitor for NF1 and Rare Diseases 12 - Minichart
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives - TipRanks
New CMO and large option grants at Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - Investing News Network
Pasithea names Kartik Krishnan as chief medical officer By Investing.com - Investing.com South Africa
Pasithea Therapeutics Appoints Kartik Krishnan as Chief Medical Officer - citybiz
Pasithea names Kartik Krishnan as chief medical officer - Investing.com
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Funicular Funds (KTTA) reports 1.84M shares, 7.4% stake in Pasithea (KTTA) - Stock Titan
KTTA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 - Investing News Network
FDA grants rare pediatric disease status to Pasithea’s PAS-004 By Investing.com - Investing.com South Africa
FDA grants rare pediatric disease status to Pasithea’s PAS-004 - Investing.com
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) - ChartMill
Pasithea Therapeutics (KTTA) Stock Employment Data (Grinds Lower) 2026-04-20Open Stock Signal Network - Newser
Coastlands Capital reveals KTTA (NASDAQ: KTTA) stake in shares and pre-funded warrants - Stock Titan
Form 3Initial statement of beneficial ownership of securities - ADVFN
Can Pasithea Therapeutics Corp grow without external funding2026 Momentum Check & Verified Short-Term Plans - baoquankhu1.vn
Should you buy the dip on Pasithea Therapeutics Corp2026 Weekly Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Loss Report: What is the next catalyst for Pasithea Therapeutics Corp Equity WarrantPortfolio Gains Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Wrap: Can Pasithea Therapeutics Corp grow without external funding2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Is Pasithea Therapeutics (KTTA) Stock Good for Passive Investors | Price at $0.76, Down 0.52%Popular Trader Picks - Newser
Opaleye/James Silverman hold 2.49M shares of Pasithea (KTTA) in Schedule 13G - Stock Titan
Aug Opening: Whats the beta of Pasithea Therapeutics Corp stockTreasury Yields & Daily Chart Pattern Signals - baoquankhu1.vn
Buyback Watch: How does Pasithea Therapeutics Corp correlate with Nasdaq2026 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Pasithea Therapeutics Corp reports results for the quarter ended December 31Earnings Summary - TradingView
KTTA Should I Buy - Intellectia AI
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - Sahm
Trade Report: Is Pasithea Therapeutics Corp stock influenced by commodity prices2026 Biggest Moves & Technical Entry and Exit Tips - baoquankhu1.vn
Pasithea receives FDA fast track status for NF1 drug candidate By Investing.com - Investing.com Australia
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity - Investing News Network
Pasithea receives FDA fast track status for NF1 drug candidate - Investing.com
Pasithea Therapeutics Announces Grant of Fast Track - GlobeNewswire
KTTA SEC FilingsPasithea Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Signal Recap: Whats the beta of Pasithea Therapeutics Corp stockDividend Hike & Verified Entry Point Detection - baoquankhu1.vn
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea (NASDAQ: KTTA) highlights PAS-004 trials and NF1 focus - Stock Titan
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Reviewing Pasithea Therapeutics (NASDAQ:KTTA) and Forte Biosciences (NASDAQ:FBRX) - Defense World
Can Pasithea Therapeutics Corp disrupt its industryMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):